SCHEMBL24519546

SCHEMBL24519546

COCCOCCOCCC(=O)N1CCC(n2nc(-c3ccc4oc(N)nc4c3)c3c(N)ncnc32)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MTOR P42345 14/20 0.57
▸ HDAC1 Q13547 8/20 0.57
▸ SRC P12931 2/20 0.53
▸ JAK2 O60674 2/20 0.52
▸ JAK3 P52333 2/20 0.52
▸ AURKA O14965 1/20 0.51
▸ AURKB Q96GD4 1/20 0.51
▸ PIK3CD O00329 4/20 0.51
▸ PIK3CA P42336 4/20 0.51
▸ PIK3CB P42338 4/20 0.51
▸ PIK3CG P48736 4/20 0.51
▸ HDAC8 Q9BY41 3/20 0.51
▸ HDAC6 Q9UBN7 3/20 0.51
▸ ABL1 P00519 2/20 0.51
▸ HDAC3 O15379 2/20 0.51
▸ HDAC2 Q92769 2/20 0.51
▸ PRKDC P78527 1/20 0.50
▸ DDR1 Q08345 1/20 0.50
▸ RICTOR Q6R327 1/20 0.48
▸ RPTOR Q8N122 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23251634 0.94 MTOR (0.59) MTORHDAC1SRCJAK2JAK3
SCHEMBL23251883 0.94 MTOR (0.59) MTORHDAC1SRCJAK2JAK3
SCHEMBL23251522 0.94 MTOR (0.57) MTORHDAC1SRCJAK2JAK3
SCHEMBL23251816 0.93 MTOR (0.57) MTORHDAC1SRCJAK2JAK3
SCHEMBL23251959 0.93 MTOR (0.57) MTORHDAC1SRCJAK2JAK3
SCHEMBL25064728 0.89 MTOR (0.62) MTORHDAC1SRCJAK2JAK3
SCHEMBL7906422 0.84 SRC (0.67) MTORHDAC1SRCPIK3CDPIK3CA
SCHEMBL25677226 0.84 MTOR (0.50) MTORHDAC1SRCPIK3CDPIK3CA
SCHEMBL23150471 0.84 MTOR (0.58) MTORHDAC1SRCPIK3CDPIK3CA
SCHEMBL30405094 0.82 SRC (0.58) MTORHDAC1SRCPIK3CDPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11364300-B2 C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors Revolution Medicines, Inc. (US) 2022-06-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11364300-B2 C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors MTOR, RICTOR, RPTOR MTOR 1/4885HDAC1 526/4885SRC 971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback